PPARD and congenital rubella syndrome: To address whether pharmacological activation of PPAR-δ attenuated behavioral abnormalities induced by CRS, we used selective PPAR-δ agonist GW0742 to treat hTau mice for 7 days following 14 days of CRS and then evaluated the behavioral outcomes (Figure 6A).